Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Sees Access Programs As Key To Growth In China, Brazil: Emerging Market Earnings Roundup (Part 1)

This article was originally published in PharmAsia News

Executive Summary

With biosimilars on the horizon, the Swiss pharma cites Herceptin and MabThera as key growth drivers in emerging markets.

You may also be interested in...



Driven By Herceptin Franchise, Roche Hopes Rituxan Will Follow Suit

The Swiss pharma reported a positive start to the year with its first quarter earnings on April 11, underscoring the strength of its oncology products as it continues to work on lifecycle management.

Playing Catchup To US, China Ups COVID Vaccination Pressure

Facing a slow roll-out of COVID-19 vaccines, China is implementing more promotional measures and increasing the pressure on the public to get inoculated. Vaccine diplomacy efforts meanwhile are facing challenges.

China Foreign Brand Boycott To Spill To Health Sector?

Amid a rising tide of sentiment against foreign consumer brands in China, observers say the impact could be far-reaching. But other factors may be more important than public opinion, and innovation will remain a key to success for health sector players.

Topics

Related Companies

UsernamePublicRestriction

Register

SC084065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel